| Literature DB >> 30004110 |
Louis Drevon1, Alice Marceau2, Odile Maarek1, Wendy Cuccuini1, Emmanuelle Clappier1, Virginie Eclache3, Thomas Cluzeau4, Valentine Richez4, Inès Berkaoui4, Sophie Dimicoli-Salazar5, Audrey Bidet5, Jean-Philippe Vial5, Sophie Park6, Christina Vieira Dos Santos6, Eléonore Kaphan6, Céline Berthon2, Aspasia Stamatoullas7, François Delhommeau8, Nassera Abermil8, Thorsten Braun3, Rosa Sapena9, Daniel Lusina3, Aline Renneville2, Lionel Adès1, Sophie Raynaud4, Pierre Fenaux1.
Abstract
Isolated trisomy 8 (+8) is a frequent cytogenetic abnormality in the myelodysplastic syndromes (MDS), but its characteristics are poorly reported. We performed a retrospective study of 138 MDS patients with isolated +8, classified or reclassified as MDS (excluding MDS/myeloproliferative neoplasm). Myeloproliferative (MP) features were defined by the repeated presence of one of the following: white blood cell count >10 × 109 /l, myelemia (presence of circulating immature granulocytes with a predominance of more mature forms) >2%, palpable splenomegaly. Fifty-four patients (39·1%) had MP features: 28 at diagnosis, 26 were acquired during evolution. MP forms had more EZH2 (33·3% vs. 12·0% in non-MP, P = 0·047), ASXL1 (66·7% vs. 42·3%, P = 0·048) and STAG2 mutations (77·8% vs. 21·7%, P = 0·006). Median event-free survival (EFS) and overall survival (OS) were 25 and 27 months for patients with MP features at diagnosis, versus 28 (P = 0·15) and 39 months (P = 0·085) for those without MP features, respectively. Among the 57 patients who received hypomethylating agent (HMA), OS was lower in MP cases (13 months vs. 23 months in non-MP cases, P = 0.02). In conclusion, MP features are frequent in MDS with isolated +8. MP forms had more EZH2, ASXL1 and STAG2 mutations, responded poorly to HMA, and tended to have poorer survival than non-MP forms.Entities:
Keywords: myelodysplastic syndromes; myelodysplastic-myeloproliferative diseases; trisomy 8
Mesh:
Substances:
Year: 2018 PMID: 30004110 DOI: 10.1111/bjh.15490
Source DB: PubMed Journal: Br J Haematol ISSN: 0007-1048 Impact factor: 6.998